-
COGT Dashboard
- Financials
- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
Cogent Biosciences (COGT)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 98.17 mm | 98.17 mm | 98.17 mm | 98.17 mm | 98.17 mm | 98.17 mm |
Cash burn (monthly) | (no burn) | (no burn) | 24.58 mm | 22.99 mm | 20.19 mm | 17.32 mm |
Cash used (since last report) | n/a | n/a | 51.11 mm | 47.82 mm | 41.99 mm | 36.01 mm |
Cash remaining | n/a | n/a | 47.05 mm | 50.34 mm | 56.17 mm | 62.15 mm |
Runway (months of cash) | n/a | n/a | 1.9 | 2.2 | 2.8 | 3.6 |
13F holders | Current |
---|---|
Total holders | 182 |
Opened positions | 37 |
Closed positions | 24 |
Increased positions | 62 |
Reduced positions | 47 |
13F shares | Current |
---|---|
Total value | 935.77 bn |
Total shares | 149.25 mm |
Total puts | 437.30 k |
Total calls | 153.10 k |
Total put/call ratio | 2.9 |
Largest owners | Shares | Value |
---|---|---|
FMR | 16.57 mm | $129.24 bn |
Venrock Healthcare Capital Partners II | 11.52 mm | $138.32 mm |
Kynam Capital Management | 9.11 mm | $71.02 bn |
BlackRock | 8.34 mm | $65.05 bn |
TCG Crossover Management | 6.96 mm | $54.32 bn |
Commodore Capital | 6.88 mm | $53.68 bn |
Fairmount Funds Management | 6.23 mm | $48.56 bn |
Vanguard | 6.13 mm | $47.84 bn |
VR Adviser | 5.68 mm | $44.34 bn |
TCG Crossover GP I | 5.63 mm | $24.95 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 25 | Jessica Sachs | Stock Option Common Stock | Grant | Acquire A | No | No | 8.89 | 270,000 | 2.40 mm | 270,000 |
23 Jan 25 | Robbins Andrew R | Stock Option Common Stock | Grant | Acquire A | No | No | 8.89 | 915,000 | 8.13 mm | 915,000 |
23 Jan 25 | Evan Kearns | Stock Option Common Stock | Grant | Acquire A | No | No | 8.89 | 230,000 | 2.04 mm | 230,000 |
23 Jan 25 | John Edward Robinson | Stock Option Common Stock | Grant | Acquire A | No | No | 8.89 | 270,000 | 2.40 mm | 270,000 |
23 Jan 25 | Cole Pinnow | Stock Option Common Stock | Grant | Acquire A | No | No | 8.89 | 240,000 | 2.13 mm | 240,000 |